BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30
• 31

• Business

  VBI Vaccines Reports First Quarter 2023 Financial Results

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2023.

  May 15, 2023

   · 

  16 min read
• Business

  Movano Health Provides Business Update and Reports First Quarter 2023 Financial Results

  Today, Movano Health (Nasdaq: MOVE), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices and makers of the Evie Ring, reported financial results for the three months ending March 31, 2023 and provided a business update.

  May 15, 2023

   · 

  11 min read
• Business

  RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights

  RenovoRx, Inc. today announced financial results for the first quarter ended March 31, 2023.

  May 15, 2023

   · 

  9 min read
• Business

  AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update

  AIM ImmunoTech Inc. reported its financial results for the first quarter 2023 and provided a business update.

  May 15, 2023

   · 

  4 min read
• Biotech Beach

  ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results

  ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today highlighted recent progress and reported first quarter 2023 financial results.

  May 15, 2023

   · 

  10 min read
• AnHorn Medicines Presents Research of Novel Protein Degrader for Topical Use at ISID Meeting 2023

  AnHorn Medicines presented its potential first-in-class protein degrader program, AH-001, at the First International Societies for Investigative Dermatology Meeting (ISID 2023) in Tokyo.

  May 15, 2023

   · 

  2 min read
• U.S. Food and Drug Administration Issues Complete Response Letter for Byondis’ [Vic-]Trastuzumab Duocarmazine

  Byondis B.V., an independent, Dutch clinical-stage biopharmaceutical company creating precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the Biological License Application (BLA) for [vic-]trastuzumab duocarmazine (SYD985).

  May 15, 2023

   · 

  2 min read
• Business

  Neurelis Announces New Roles for Top Executives to Advance Clinical and Strategic Initiatives and Position for Future Growth

  Neurelis, Inc., announced the promotion of Adrian L. Rabinowicz, MD, to Chief Medical Officer and the establishment of a new leadership position of Senior Vice President, Strategic Initiatives for Enrique Carrazana, MD.

  May 15, 2023

   · 

  8 min read
• Genetown

  Boston Scientific to Participate in Bernstein’s 39th Annual Strategic Decisions Conference

  Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein’s 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023.

  May 15, 2023

   · 

  1 min read
• Deals

  PARI acquires Nortev, the manufacturer of the equine inhaler Flexineb®

  PARI, manufacturer of medical devices and pharmaceuticals in the field of respiratory and inhalation, today announced the acquisition of the Irish company Nortev.

  May 15, 2023

   · 

  3 min read